FDA Greenlights SofdraTM for Hyperhidrosis Treatment, Botanix Secures $70M

For the purpose of treating primary axillary hyperhidrosis, Botanix Pharmaceuticals Limited's innovative dermatological treatment, SofdraTM, has been approved by the FDA. Through a successful placement, the business has secured $70 million to finance the launch, which is scheduled to start with a patient experience program in Q3 2024 and move into a more comprehensive digital release in Q4. With no debt and a healthy financial position, Botanix is well-positioned to take on the roughly 10 million Americans who suffer from this illness.